Petaling Jaya, 13 April 2022 – Honda Malaysia (or the Company) today introduced a new variant to the All-New City Hatchback line-up, the V-SENSING. Priced at RM91,708.51 *¹, the All-New City Hatchback V-SENSING is ideal for young executives and young families with an active lifestyle - who enjoys a cool and sporty ride with added advanced safety features for their daily commute. This new variant together with the RS e:HEV variant in the All-New City Hatchback line-up are both equipped with Honda SENSING, the most complete advanced safety features in its class.
Honda Malaysia Managing Director and Chief Executive Officer, Mr. Hironobu Yoshimura said, “Throughout the years, the City is well-known for its safety and advanced technology. We introduced the City V-SENSING variant to the City line-up in November 2021, and our record shows that it has been well accepted in its segment. For the first quarter of 2022, the City V-SENSING contributed 34% to the total City sales, which shows a positive trend for this variant and also the recognition of Honda SENSING, our advanced safety technology. We are now excited to introduce the V-SENSING variant to the All-New City Hatchback. We believe that with two All-New City Hatchback variants now available with Honda SENSING, it will further add value for our customers while raising the benchmark in the segment.
CYBERJAYA, April 13 (Bernama) -- Hematogenix, the first central oncology clinical trials lab in Malaysia, brings the nation a step closer to making it the preferred destination in the region for clinical research. The facility in Cyberjaya, which was visited earlier today by the Minister of Health YB Khairy Jamaluddin, has been operational since June 2021, providing specialized services for cancer research.
Hematogenix is the sole facility within the Asia Pacific region to be CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified. Its strategic location positions Malaysia as a hub for the Asia Pacific region in providing highly specialized central laboratory support in clinical research. Hematogenix Malaysia offers an exclusive scope of services within the region,that are often sought for by organizations conducting clinical trials. Currently the facility is managing at least 10 clinical studies from multinational global pharmaceutical companies and has processed over 800 shipments of biological specimens delivered to their facility in Cyberjaya from study sites across Asia Pacific namely Japan, South Korea, Taiwan, and Australia.
KUALA LUMPUR, April 13 (Bernama) -- KLCCP Stapled Group held the KLCC Real Estate Investment Trust’s 9th Annual General Meeting and KLCC Property Holdings Berhad’s 19th Annual General Meeting (AGM) today, presenting to its shareholders the Group’s performance for the financial year ended 31 December 2021. Due to concerns for the health & safety of the shareholders, the Meeting was held in a virtual mode under strict Covid-19 Standard Operating Procedures (SOPs) and broadcasted live to the shareholders.
Highlights of FY2021
• Recorded a revenue of RM1.2 billion and a 3.2% increase in Profit Before Tax (PBT) for the financial year ended 31 December 2021, anchored by the stable office segment, with full occupancy and long-term leases
